Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Raised by Boston Common Asset Management LLC

Boston Common Asset Management LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 49,752 shares of the medical equipment provider’s stock after purchasing an additional 528 shares during the period. Boston Common Asset Management LLC’s holdings in Zimmer Biomet were worth $5,255,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BLB&B Advisors LLC boosted its holdings in shares of Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares during the period. FWG Holdings LLC raised its stake in shares of Zimmer Biomet by 2.9% during the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after purchasing an additional 101 shares in the last quarter. Financial Advocates Investment Management increased its stake in Zimmer Biomet by 3.5% during the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 103 shares during the period. M&R Capital Management Inc. increased its stake in shares of Zimmer Biomet by 14.1% during the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock valued at $92,000 after acquiring an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC lifted its holdings in shares of Zimmer Biomet by 5.1% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 106 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.7 %

ZBH stock opened at $109.65 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The company has a 50-day moving average of $107.81 and a two-hundred day moving average of $107.97. The stock has a market capitalization of $21.83 billion, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.65 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Analyst Ratings Changes

ZBH has been the topic of several recent analyst reports. Oppenheimer cut their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. BTIG Research decreased their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Evercore ISI lowered their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Raymond James dropped their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.